Galderma Laboratories LP v. Actavis Laboratories UT Inc

Application Number	Patent Number	External Links
-	US8362069	Espacenet Google Patents
-	US8815816	Espacenet Google Patents
-	US9089587	Espacenet Google Patents
-	US9233117	Espacenet Google Patents
-	US9233118	Espacenet Google Patents
-	US9782425	Espacenet Google Patents

COMPLAINT against All Defendants filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (Filing fee $400; Receipt number 0539-8360927) Clerk to issue summons(es). In each Notice of Electronic Filing, the judge assignment is indicated, and a link to the Judges Copy Requirements is provided. The court reminds the filer that any required copy of this and future documents must be delivered to the judge, in the manner prescribed, within three business days of filing. Unless exempted, attorneys who are not admitted to practice in the Northern District of Texas must seek admission promptly. Forms, instructions, and exemption information may be found at www.txnd.uscourts.gov, or by clicking here: Attorney Information - Bar Membership. If admission requirements are not satisfied within 21 days, the clerk will notify the presiding judge. (Attachments: # 1 Exhibit(s) A - US Patent No. 8,362,069, # 2 Exhibit(s) B - US Patent No. 8,815,816, # 3 Exhibit(s) C - US Patent No. 9,089,587, # 4 Exhibit(s) D - US Patent No. 9,233,117, # 5 Exhibit(s) E - US Patent No. 9,233,118, # 6 Cover Sheet) (Alibhai, Jamil) (Entered: 04/21/2017)

2017-04-21

1

View

CERTIFICATE OF INTERESTED PERSONS/DISCLOSURE STATEMENT by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. Galderma Laboratories, L.P. is a subsidiary owned by Galderma Limited LLC and Galderma General LLC. Galderma S.A. is a wholly-owned subsidiary of Galderma Pharma S.A. Nestl Skin Health SA is a wholly-owned subsidiary of Nestl SA. (Alibhai, Jamil) Modified text on 4/21/2017 (ykp). (Entered: 04/21/2017)

2017-04-21

1

View

New Case Notes: A filing fee has been paid. Pursuant to Misc. Order 6, Plaintiff is provided the Notice of Right to Consent to Proceed Before A U.S. Magistrate Judge (Judge Stickney). Clerk to provide copy to plaintiff if not received electronically. (ykp) (Entered: 04/21/2017)

2017-04-21

1

View

Summons Issued as to Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (ykp) (Entered: 04/21/2017)

2017-04-21

1

View

Report to Patent/Trademark Office of Initiating Document. Form AO 120 e-mailed to notice_of_suit@uspto.gov. (ykp) (Entered: 04/21/2017)

2017-04-21

1

View

Case Reassigned to Chief Judge Barbara M.G. Lynn. Judge Sam A Lindsay no longer assigned to the case. (cea)

2017-04-24

1

No Actions

WAIVER OF SERVICE Returned Executed as to Actavis Laboratories UT Inc. Waiver sent on 5/15/2017; TEVA Pharmaceuticals USA Inc. Waiver sent on 5/15/2017. (Alibhai, Jamil) (Entered: 05/16/2017)

2017-05-16

1

View

NOTICE of Attorney Appearance by Scott W Breedlove on behalf of Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Filer confirms contact info in ECF is current.) (Breedlove, Scott) (Entered: 06/21/2017)

2017-06-21

1

View

NOTICE of Attorney Appearance by E Leon Carter on behalf of Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Filer confirms contact info in ECF is current.) (Carter, E) (Entered: 06/21/2017)

2017-06-21

1

View

ORDER: Pretrial Conference set for 7/13/2017 at 8:30 AM in US Courthouse, Courtroom 1570, 1100 Commerce St., Dallas, TX 75242-1310 before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 6/23/2017) (ran) (Entered: 06/26/2017)

2017-06-23

1

View

SUMMONS Returned Executed as to Teva Pharmaceutical Industries Ltd. ; served on 6/22/2017. (ndt) (Entered: 06/29/2017)

2017-06-28

1

View

ORDER: Pretrial Conference reset for 8/2/2017 03:00 PM in US Courthouse, Courtroom 1570, 1100 Commerce St., Dallas, TX 75242-1310 before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 6/29/2017) (ndt) (Entered: 06/29/2017)

2017-06-29

1

View

AMENDED DOCUMENT by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. Amendment to 10 Summons Returned. Amended Proof of Service of Summons as to Teva Pharmaceutical Industries Ltd.(Alibhai, Jamil) Modified on 7/7/2017 (ykp). (Entered: 07/06/2017)

2017-07-06

1

View

NOTICE of Attorney Appearance by E Leon Carter on behalf of Teva Pharmaceutical Industries Ltd.. (Filer confirms contact info in ECF is current.) (Carter, E) (Entered: 07/10/2017)

2017-07-10

1

View

NOTICE of Attorney Appearance by Scott W Breedlove on behalf of Teva Pharmaceutical Industries Ltd.. (Filer confirms contact info in ECF is current.) (Breedlove, Scott) (Entered: 07/10/2017)

2017-07-10

1

View

AMENDED COMPLAINT WITH JURY DEMAND against All Defendants filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. Unless exempted, attorneys who are not admitted to practice in the Northern District of Texas must seek admission promptly. Forms, instructions, and exemption information may be found at www.txnd.uscourts.gov, or by clicking here: Attorney Information - Bar Membership. If admission requirements are not satisfied within 21 days, the clerk will notify the presiding judge. (Attachments: # 1 Exhibit(s) A, # 2 Exhibit(s) B, # 3 Exhibit(s) C, # 4 Exhibit(s) D, # 5 Exhibit(s) E) (Alibhai, Jamil) (Entered: 07/10/2017)

2017-07-10

1

View

Request for Clerk to issue Summons filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (Alibhai, Jamil) (Entered: 07/10/2017)

2017-07-10

1

View

Summons Issued as to Teva Pharmaceutical Industries Ltd. (ndt) (Entered: 07/10/2017)

2017-07-10

1

View

Unopposed Motion for Extension of Time to File Answer Subject to Special Appearance filed by Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 07/10/2017)

2017-07-10

1

View

ELECTRONIC ORDER granting 18 unopposed Motion for Extension of Time to File Answer. The deadline for Teva Pharmaceutical Industries Ltd. to file and serve an answer to the complaint or a motion under FRCP 12 is extended to 7/28/2017. (Ordered by Chief Judge Barbara M.G. Lynn on 7/11/2017) (chmb) (Entered: 07/11/2017)

2017-07-11

1

View

SUMMONS Returned Executed as to Teva Pharmaceutical Industries Ltd; served on 7/13/2017. (ran) (Entered: 07/19/2017)

2017-07-19

1

View

MOTION to Dismiss First Amended Complaint for Patent Infringement filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc (Carter, E) (Entered: 07/21/2017)

2017-07-21

1

View

DISREGARD - see 23 for corrected image Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Carter, E) Modified per attorney on 7/24/2017 (sss). (Entered: 07/21/2017)

2017-07-21

1

View

Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Carter, E) (Entered: 07/21/2017)

2017-07-21

1

View

CERTIFICATE OF INTERESTED PERSONS/DISCLOSURE STATEMENT by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Breedlove, Scott) (Main Document 24 replaced on 7/24/2017) (dss). (Entered: 07/24/2017)

2017-07-24

1

View

MOTION to Dismiss filed by Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 07/27/2017)

2017-07-27

1

View

ORDER REQUIRING SCHEDULING CONFERENCE AND REPORT FOR CONTENTS OF SCHEDULING ORDER FOR PATENT CASE: Lead counsel for each party (or a designee attorney with appropriate authority) and any unrepresented party (except for a prisoner litigant proceeding pro se) shall confer as soon as practicable, but in any event no later than 8/18/2017. Joint Report due by 8/25/2017. (Ordered by Chief Judge Barbara M.G. Lynn on 7/27/2017) (ykp) (Entered: 07/27/2017)

2017-07-27

1

View

ORDER RESETTING RULE 16 CONFERENCE: The Rule 16 Conference is reset for 9/18/2017 09:00 AM in US Courthouse, Courtroom 1570, 1100 Commerce St., Dallas, TX 75242-1310 before Chief Judge Barbara M.G. Lynn. All lead counsel must attend in person. (Ordered by Chief Judge Barbara M.G. Lynn on 7/27/2017) (ykp) (Entered: 07/27/2017)

2017-07-27

1

View

RESPONSE filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re: 25 MOTION to Dismiss (Alibhai, Jamil) (Entered: 08/11/2017)

2017-08-11

1

View

Appendix in Support filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re 28 Response/Objection TO DEFENDANT TEVA PHARMACEUTICAL INDUSTRIES LTD.S MOTION TO DISMISS (Attachments: # 1 Exhibit(s) A - Declaration of Jamil N. Alibhai, # 2 Exhibit(s) 1 - Excerpts Teva's Form 20-F, # 3 Exhibit(s) 2 - Teva's 2nd Quarter 2017 Press Release) (Alibhai, Jamil) (Entered: 08/11/2017)

2017-08-11

1

View

RESPONSE AND OBJECTION filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Alibhai, Jamil) (Entered: 08/11/2017)

2017-08-11

1

View

Appendix in Support filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re 30 Response/Objection to Defendants' Motion to Dismiss (Attachments: # 1 Declaration(s) A - Declaration Steven B. Midgley, # 2 Exhibit(s) A-1 - Excerpts from Tevas Paragraph IV Notice, # 3 Declaration(s) B - Declaration Jamil N. Alibhai, # 4 Exhibit(s) B-1 - Excerpts from Tevas Form 20-F, # 5 Exhibit(s) B-2 - Teva Company Profile, # 6 Exhibit(s) B-3 - About Teva Generics, # 7 Exhibit(s) B-4 - Teva Investigational Sites, # 8 Exhibit(s) B-5 - Actavis Property Tax Appraisal, # 9 Exhibit(s) B-6 - Dallas Business Center, # 10 Exhibit(s) B-7 - Allergan Acquisition Press Release, # 11 Exhibit(s) B-8 - Teva USA License No. 38025, # 12 Exhibit(s) B-9 - Teva USA License No. 93252, # 13 Exhibit(s) B-10 - Actavis License No. 74065, # 14 Exhibit(s) B-11 - Teva & Actavis Authorized Distributors, # 15 Exhibit(s) B-12 - Teva LinkedIn Profiles, # 16 Exhibit(s) B-13 - Actavis LinkedIn Profiles, # 17 Exhibit(s) B-14 - Exhibit 37 to Aralez's Response, # 18 Exhibit(s) B-15 - Teva Job Postings, # 19 Exhibit(s) B-16 - Forest Aquisition Press Release, # 20 Exhibit(s) B-17 - Teva's Acorda Amicus Brief, # 21 Exhibit(s) B-18 - Teva Reply, # 22 Exhibit(s) B-19 - Actavis v. USB Complaint) (Alibhai, Jamil) (Entered: 08/11/2017)

2017-08-11

1

View

Application for Admission Pro Hac Vice with Certificate of Good Standing (Filing fee $25; Receipt number 0539-8607662) filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Certificate of Good Standing, # 2 Proposed Order)Attorney Leora Ben-Ami added to party Actavis Laboratories UT Inc(pty:dft), Attorney Leora Ben-Ami added to party TEVA Pharmaceuticals USA Inc(pty:dft), Attorney Leora Ben-Ami added to party Teva Pharmaceutical Industries Ltd.(pty:dft) (Ben-Ami, Leora) (Entered: 08/17/2017)

2017-08-17

1

View

MOTION for Extension of Time to File Response/Reply to 30 Response/Objection, 28 Response/Objection filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 08/18/2017)

2017-08-18

1

View

ELECTRONIC ORDER granting 32 Application for Admission Pro Hac Vice of Leora Ben-Ami. If not already done, Applicant must register as an ECF User within 14 days (LR 5.1(f)). (Ordered by Chief Judge Barbara M.G. Lynn on 8/18/2017) (lag/chmb) (Entered: 08/18/2017)

2017-08-18

1

View

ELECTRONIC ORDER granting 33 Motion to Extend Time to File Replies. Defendants' deadline to file and serve their replies to Plaintiffs' Responses in Opposition to Defendants' Motions to Dismiss is extended to September 1, 2017. (Ordered by Chief Judge Barbara M.G. Lynn on 8/21/2017) (chmb) (Entered: 08/21/2017)

2017-08-21

1

View

Joint STATUS REPORT Regarding Contents of Scheduling Order filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (Attachments: # 1 Exhibit(s) A) (Alibhai, Jamil) (Entered: 08/25/2017)

2017-08-25

1

View

Application for Admission Pro Hac Vice with Certificate of Good Standing (Filing fee $25; Receipt number 0539-8636974) filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Certificate of Good Standing, # 2 Proposed Order)Attorney Thomas F Fleming added to party Actavis Laboratories UT Inc(pty:dft), Attorney Thomas F Fleming added to party TEVA Pharmaceuticals USA Inc(pty:dft), Attorney Thomas F Fleming added to party Teva Pharmaceutical Industries Ltd.(pty:dft) (Fleming, Thomas) (Entered: 08/30/2017)

2017-08-30

1

View

REPLY filed by Teva Pharmaceutical Industries Ltd. re: 25 MOTION to Dismiss (Breedlove, Scott) (Entered: 09/01/2017)

2017-09-01

1

View

REPLY filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Attachments: # 1 Exhibit(s) Appendix in Support) (Breedlove, Scott) (Entered: 09/01/2017)

2017-09-01

1

View

NOTICE of Plaintiffs' Compliance with P.R. 3-1 & 3-2 filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Alibhai, Jamil) (Entered: 09/07/2017)

2017-09-07

1

View

ELECTRONIC ORDER granting 37 Application for Admission Pro Hac Vice of Thomas F. Fleming. If not already done, Applicant must register as an ECF User within 14 days (LR 5.1(f)). (Ordered by Chief Judge Barbara M.G. Lynn on 9/8/2017) (lag/chmb) (Entered: 09/08/2017)

2017-09-08

1

View

NOTICE of Supplemental Authority re: 30 Response/Objection filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Attachments: # 1 Exhibit(s) A - Bristol-Myers Squibb Co. v. Mylan Pharms Inc, # 2 Exhibit(s) B - Kranos IP Corp. v. Riddell Inc) (Alibhai, Jamil) (Entered: 09/12/2017)

2017-09-12

1

View

NOTICE of Supplemental Authority re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement, 42 Notice (Other), filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc (Breedlove, Scott) (Entered: 09/18/2017)

2017-09-18

1

View

Minute Entry for proceedings held before Chief Judge Barbara M.G. Lynn: Scheduling Conference held on 9/18/2017. Attorney Appearances: Plaintiff - Jamil Alibhai, Michael Wilson, Jordan Strauss, Chase Cobern; Defense - Leora Ben-Ami, Scott Breedlove, Leon Carter. (Court Reporter: Keith Johnson) (No exhibits) Time in Court - :35. (ndt) Modified docket text on 9/18/2017 (ndt). (Entered: 09/18/2017)

2017-09-18

1

View

ORDER SETTING HEARING: The Court SETS (1) the Motion to Dismiss under Fed. R. Civ. P. 12(b)(3) for improper venue [ECF # 21 ], filed by Actavis Laboratories UT Inc. and TEVA Pharmaceuticals USA Inc.; and (2) the Motion to Dismiss under Fed. R. Civ. P. 12(b) [ECF # 25 ], filed by Teva Pharmaceutical Industries Ltd., for oral argument on 10/24/2017, at 1:00 p.m. Counsel should convene in Courtroom 1570, Earle Cabell Federal Building, 1100 Commerce Street, Dallas, Texas. (Ordered by Chief Judge Barbara M.G. Lynn on 9/18/2017) (sss) (Entered: 09/19/2017)

2017-09-18

1

View

ELECTRONIC Minute Entry for proceedings held before Chief Judge Barbara M.G. Lynn: Telephone Conference held on 10/3/2017, in this patent infringement action to discuss Plaintiff's request for venue discovery. As stated on the record, the Court will allow Plaintiff to conduct the following limited discovery: (1) a 1 hour deposition of Jocelyn Baker; (2) a 1 hour deposition of Defendants' 30(b)(6) witness; and (3) 15 interrogatories narrowly tailored to the areas of relevant inquiry identified in In re Cray, 2017 WL 4201535 (Fed. Cir. Sept. 21, 2017). Plaintiff will submit its proposed interrogatories to the Court for approval before serving them on Defendants. Attorney Appearances: Plaintiff - Jamil Alibhai, Michael Wilson; Defense - Leora Ben-Ami, Scott Breedlove, Leon Carter. (Court Reporter: Keith Johnson) (No exhibits) Time in Court - 0:30. (lag/chmb) (Entered: 10/03/2017)

2017-10-03

1

View

MOTION for Leave to File First Amended Complaint for Patent Infringement filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Attachments: # 1 Exhibit(s) A - First Supplemental Complaint for Patent Infringement, # 2 Exhibit(s) F - U.S. Patent 9,782,425B2, # 3 Proposed Order) (Alibhai, Jamil) (Entered: 10/13/2017)

2017-10-13

1

View

ORDER RESETTING HEARING: Motion Hearing reset for 11/6/2017 at 1:00 PM before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 10/19/2017) (ran) (Entered: 10/20/2017)

2017-10-19

1

View

NOTICE of Compliance with Paragraphs 3-3 and 3-4 filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Carter, E) (Entered: 10/24/2017)

2017-10-24

1

View

RESPONSE filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. re: 47 MOTION for Leave to File First Amended Complaint for Patent Infringement (Breedlove, Scott) (Entered: 10/31/2017)

2017-10-31

1

View

Notice of Filing of Official Electronic Transcript of Rule 16 Proceedings held on September 18, 2017 before Judge Lynn. Court Reporter/Transcriber D. Keith Johnson, Telephone number 214-753-2325. Parties are notified of their duty to review the transcript. A copy may be purchased from the court reporter or viewed at the clerk's office. If redaction is necessary, a Redaction Request - Transcript must be filed within 21 days. If no such Request is filed, the transcript will be made available via PACER without redaction after 90 calendar days. If redaction request filed, this transcript will not be accessible via PACER; see redacted transcript. The clerk will mail a copy of this notice to parties not electronically noticed. (53 pages) Redaction Request due 11/22/2017. Redacted Transcript Deadline set for 12/4/2017. Release of Transcript Restriction set for 1/30/2018. (dkj) (Main Document 51 replaced on 11/6/2017 with corrected transcript) (chmb). (Entered: 11/01/2017)

2017-11-01

1

View

NOTICE of Dismissal Without Prejudice filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Alibhai, Jamil) (Entered: 11/02/2017)

2017-11-02

1

View

Appendix in Support filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re 30 Response/Objection Supplemental Appendix (Attachments: # 1 Declaration(s) of Jamil Alibhai, # 2 Exhibit(s) C1-Plaintiffs Second Amended Notice of Rule 30(b)(6) Deposition of Defendants Teva USA and Actavis, # 3 Exhibit(s) C2-Excerpts from Teva Pharmaceutical Industries Limiteds 20-F, # 4 Exhibit(s) C3-Teva USA Specialty Medicines, # 5 Exhibit(s) C4-21 C.F.R. §§ 203.30-.35 (2017), # 6 Exhibit(s) C5-Excerpts of Teva USA Code of Conduct, # 7 Exhibit(s) C6-Compiled Teva USA Phone Listings in NDTX, # 8 Exhibit(s) C7-Answer to Complaint (Keen v. Teva), # 9 Exhibit(s) C8-Affidavit of Robert Bobrowski (Keen v. Teva), # 10 Exhibit(s) C9-Excerpts of Oral Deposition of Robert Bobrowski (Keen v. Teva), # 11 Exhibit(s) C10-Letter from Robert Bobrowski (Keen v. Teva), # 12 Exhibit(s) C11-Answer to Plaintiffs Complaint (Stavropoulos v. Teva), # 13 Exhibit(s) C12-Teva Pharmaceuticals USA, Inc. Annual Report filed with the Vermont Secretary of State, # 14 Exhibit(s) C13-Teva Sales and Marketing, Inc. Annual Report filed with the West Virginia Secretary of State) (Alibhai, Jamil) (Entered: 11/02/2017)

2017-11-02

1

View

(Document Restricted) Plaintiffs' Motion for Leave to File Exhibits C14, C15, D and E to Plaintiffs Supplemental Appendix Under Seal (Sealed pursuant to motion to seal) filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Attachments: # 1 Exhibit(s) C14-Oral Deposition of Barbara Scoll, # 2 Exhibit(s) C15-Defendants Supplemental Responses and Objections to Plaintiffs Venue-Related Interrogatories, # 3 Exhibit(s) D-Declaration of Lucy Hutchison, # 4 Exhibit(s) E-Declaration of Danielle Wheatley, # 5 Proposed Order Proposed Order Granting Motion for Leave to File Under Seal) (Alibhai, Jamil) (Entered: 11/02/2017)

2017-11-02

1

View

Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement SUPPLEMENTAL (Breedlove, Scott) (Entered: 11/02/2017)

2017-11-02

1

View

ELECTRONIC ORDER granting sealed and/or ex parte motion 54 . Exhibits C14, C15, D, and E to Galderma's Supplemental Appendix shall be filed under seal. (Clerk to enter the sealed and/or ex parte document as of the date of this order.) (Ordered by Chief Judge Barbara M.G. Lynn on 11/6/2017) (chmb) (Entered: 11/06/2017)

2017-11-06

1

View

(Document Restricted) Sealed Exhibits C14, C15, D, and E re: 53 Appendix in Support filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (epm) (Entered: 11/06/2017)

2017-11-06

1

View

(Document Restricted) Sealed MEMORANDUM OPINION AND ORDER granting 21 Motion to Dismiss First Amended Complaint for Patent Infringement, 25 Motion to Dismiss, 47 Motion for Leave to File First Amended Complaint for Patent Infringement. (Ordered by Chief Judge Barbara M.G. Lynn on 11/17/2017) (aaa) (Entered: 11/17/2017)

2017-11-17

1

View

AMENDED COMPLAINT WITH JURY DEMAND against Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. If additional patent or trademark numbers are included, the clerk will prepare the appropriate Report to the Patent/Trademark or Copyright Office. Unless exempted, attorneys who are not admitted to practice in the Northern District of Texas must seek admission promptly. Forms, instructions, and exemption information may be found at www.txnd.uscourts.gov, or by clicking here: Attorney Information - Bar Membership. If admission requirements are not satisfied within 21 days, the clerk will notify the presiding judge. (aaa) (Entered: 11/17/2017)

2017-11-17

1

View

MEMORANDUM OPINION AND ORDER granting 21 Motion to Dismiss First Amended Complaint for Patent Infringement, 25 Motion to Dismiss, 47 Motion for Leave to File First Amended Complaint for Patent Infringement. (Ordered by Chief Judge Barbara M.G. Lynn on 11/17/2017) (twd)

2017-11-17

1

Download

Agreed MOTION to Dismiss Defendant Teva Pharmaceutical Industries Ltd. Without Prejudice filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Wilson, Michael) (Entered: 12/08/2017)

2017-12-08

1

View

ORDER granting 61 Motion to Dismiss Teva Pharmaceutical Industries LTD Without Prejudice. (Ordered by Chief Judge Barbara M.G. Lynn on 12/11/2017) (rekc) (Entered: 12/11/2017)

2017-12-11

1

View

Order Transferring to Another District: Case transferred to District of Delaware. (Ordered by Chief Judge Barbara M.G. Lynn on 12/11/2017) (rekc) (Entered: 12/11/2017)

2017-12-11

1

View

Report to Patent/Trademark Office of Final Order. Form AO 120 e-mailed to notice_of_suit@uspto.gov. (rekc) (Entered: 12/11/2017)

2017-12-11

1

View

Case transferred from NDTX has been opened in District of Delaware as case number 1:17-cv-01783. (rekc)

2017-12-11

1

No Actions

Interdistrict Transfer to District of Delaware; notice sent via email. All documents available electronically. If receiving court cannot upload, they should request restricted documents from this court and obtain public documents from PACER. Counsel advised to file future documents in District of Delaware. (rekc)

2017-12-11

1

No Actions

Chief Judge Barbara M.G. Lynn added. (ali)

2017-12-12

1

No Actions

Overview

Parties

Defendant

Actavis Laboratories UT Inc Follow

Represented By

Plaintiff

Galderma Laboratories LP Follow

Represented By

Court & Judges

Patents Involved

Docket Entries

New Case Notes: A filing fee has been paid. Pursuant to Misc. Order 6, Plaintiff is provided the Notice of Right to Consent to Proceed Before A U.S. Magistrate Judge (Judge Stickney). Clerk to provide copy to plaintiff if not received electronically. (ykp) (Entered: 04/21/2017)

Summons Issued as to Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (ykp) (Entered: 04/21/2017)

Report to Patent/Trademark Office of Initiating Document. Form AO 120 e-mailed to notice_of_suit@uspto.gov. (ykp) (Entered: 04/21/2017)

Case Reassigned to Chief Judge Barbara M.G. Lynn. Judge Sam A Lindsay no longer assigned to the case. (cea)

WAIVER OF SERVICE Returned Executed as to Actavis Laboratories UT Inc. Waiver sent on 5/15/2017; TEVA Pharmaceuticals USA Inc. Waiver sent on 5/15/2017. (Alibhai, Jamil) (Entered: 05/16/2017)

NOTICE of Attorney Appearance by Scott W Breedlove on behalf of Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Filer confirms contact info in ECF is current.) (Breedlove, Scott) (Entered: 06/21/2017)

NOTICE of Attorney Appearance by E Leon Carter on behalf of Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Filer confirms contact info in ECF is current.) (Carter, E) (Entered: 06/21/2017)

ORDER: Pretrial Conference set for 7/13/2017 at 8:30 AM in US Courthouse, Courtroom 1570, 1100 Commerce St., Dallas, TX 75242-1310 before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 6/23/2017) (ran) (Entered: 06/26/2017)

SUMMONS Returned Executed as to Teva Pharmaceutical Industries Ltd. ; served on 6/22/2017. (ndt) (Entered: 06/29/2017)

ORDER: Pretrial Conference reset for 8/2/2017 03:00 PM in US Courthouse, Courtroom 1570, 1100 Commerce St., Dallas, TX 75242-1310 before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 6/29/2017) (ndt) (Entered: 06/29/2017)

AMENDED DOCUMENT by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. Amendment to 10 Summons Returned. Amended Proof of Service of Summons as to Teva Pharmaceutical Industries Ltd.(Alibhai, Jamil) Modified on 7/7/2017 (ykp). (Entered: 07/06/2017)

NOTICE of Attorney Appearance by E Leon Carter on behalf of Teva Pharmaceutical Industries Ltd.. (Filer confirms contact info in ECF is current.) (Carter, E) (Entered: 07/10/2017)

NOTICE of Attorney Appearance by Scott W Breedlove on behalf of Teva Pharmaceutical Industries Ltd.. (Filer confirms contact info in ECF is current.) (Breedlove, Scott) (Entered: 07/10/2017)

Request for Clerk to issue Summons filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (Alibhai, Jamil) (Entered: 07/10/2017)

Summons Issued as to Teva Pharmaceutical Industries Ltd. (ndt) (Entered: 07/10/2017)

Unopposed Motion for Extension of Time to File Answer Subject to Special Appearance filed by Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 07/10/2017)

SUMMONS Returned Executed as to Teva Pharmaceutical Industries Ltd; served on 7/13/2017. (ran) (Entered: 07/19/2017)

MOTION to Dismiss First Amended Complaint for Patent Infringement filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc (Carter, E) (Entered: 07/21/2017)

***DISREGARD - see 23 for corrected image*** Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Carter, E) Modified per attorney on 7/24/2017 (sss). (Entered: 07/21/2017)

Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Carter, E) (Entered: 07/21/2017)

CERTIFICATE OF INTERESTED PERSONS/DISCLOSURE STATEMENT by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc. (Breedlove, Scott) (Main Document 24 replaced on 7/24/2017) (dss). (Entered: 07/24/2017)

MOTION to Dismiss filed by Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 07/27/2017)

RESPONSE filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re: 25 MOTION to Dismiss (Alibhai, Jamil) (Entered: 08/11/2017)

RESPONSE AND OBJECTION filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Alibhai, Jamil) (Entered: 08/11/2017)

MOTION for Extension of Time to File Response/Reply to 30 Response/Objection, 28 Response/Objection filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Attachments: # 1 Proposed Order) (Breedlove, Scott) (Entered: 08/18/2017)

ELECTRONIC ORDER granting 32 Application for Admission Pro Hac Vice of Leora Ben-Ami. If not already done, Applicant must register as an ECF User within 14 days (LR 5.1(f)). (Ordered by Chief Judge Barbara M.G. Lynn on 8/18/2017) (lag/chmb) (Entered: 08/18/2017)

Joint STATUS REPORT Regarding Contents of Scheduling Order filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (Attachments: # 1 Exhibit(s) A) (Alibhai, Jamil) (Entered: 08/25/2017)

REPLY filed by Teva Pharmaceutical Industries Ltd. re: 25 MOTION to Dismiss (Breedlove, Scott) (Entered: 09/01/2017)

REPLY filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Attachments: # 1 Exhibit(s) Appendix in Support) (Breedlove, Scott) (Entered: 09/01/2017)

NOTICE of Plaintiffs' Compliance with P.R. 3-1 & 3-2 filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Alibhai, Jamil) (Entered: 09/07/2017)

ELECTRONIC ORDER granting 37 Application for Admission Pro Hac Vice of Thomas F. Fleming. If not already done, Applicant must register as an ECF User within 14 days (LR 5.1(f)). (Ordered by Chief Judge Barbara M.G. Lynn on 9/8/2017) (lag/chmb) (Entered: 09/08/2017)

NOTICE of Supplemental Authority re: 30 Response/Objection filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Attachments: # 1 Exhibit(s) A - Bristol-Myers Squibb Co. v. Mylan Pharms Inc, # 2 Exhibit(s) B - Kranos IP Corp. v. Riddell Inc) (Alibhai, Jamil) (Entered: 09/12/2017)

NOTICE of Supplemental Authority re: 21 MOTION to Dismiss First Amended Complaint for Patent Infringement, 42 Notice (Other), filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc (Breedlove, Scott) (Entered: 09/18/2017)

ORDER RESETTING HEARING: Motion Hearing reset for 11/6/2017 at 1:00 PM before Chief Judge Barbara M.G. Lynn. (Ordered by Chief Judge Barbara M.G. Lynn on 10/19/2017) (ran) (Entered: 10/20/2017)

NOTICE of Compliance with Paragraphs 3-3 and 3-4 filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. (Carter, E) (Entered: 10/24/2017)

RESPONSE filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc, Teva Pharmaceutical Industries Ltd. re: 47 MOTION for Leave to File First Amended Complaint for Patent Infringement (Breedlove, Scott) (Entered: 10/31/2017)

NOTICE of Dismissal Without Prejudice filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Alibhai, Jamil) (Entered: 11/02/2017)

Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement SUPPLEMENTAL (Breedlove, Scott) (Entered: 11/02/2017)

(Document Restricted) Sealed Exhibits C14, C15, D, and E re: 53 Appendix in Support filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA. (epm) (Entered: 11/06/2017)

MEMORANDUM OPINION AND ORDER granting 21 Motion to Dismiss First Amended Complaint for Patent Infringement, 25 Motion to Dismiss, 47 Motion for Leave to File First Amended Complaint for Patent Infringement. (Ordered by Chief Judge Barbara M.G. Lynn on 11/17/2017) (twd)

Agreed MOTION to Dismiss Defendant Teva Pharmaceutical Industries Ltd. Without Prejudice filed by Galderma Laboratories LP, Galderma SA, Nestle Skin Health SA (Wilson, Michael) (Entered: 12/08/2017)

ORDER granting 61 Motion to Dismiss Teva Pharmaceutical Industries LTD Without Prejudice. (Ordered by Chief Judge Barbara M.G. Lynn on 12/11/2017) (rekc) (Entered: 12/11/2017)

Order Transferring to Another District: Case transferred to District of Delaware. (Ordered by Chief Judge Barbara M.G. Lynn on 12/11/2017) (rekc) (Entered: 12/11/2017)

Report to Patent/Trademark Office of Final Order. Form AO 120 e-mailed to notice_of_suit@uspto.gov. (rekc) (Entered: 12/11/2017)

Case transferred from NDTX has been opened in District of Delaware as case number 1:17-cv-01783. (rekc)

Chief Judge Barbara M.G. Lynn added. (ali)

Track Case Updates

Actavis Laboratories UT Inc

Galderma Laboratories LP

DISREGARD - see 23 for corrected image Appendix in Support filed by Actavis Laboratories UT Inc, TEVA Pharmaceuticals USA Inc re 21 MOTION to Dismiss First Amended Complaint for Patent Infringement (Carter, E) Modified per attorney on 7/24/2017 (sss). (Entered: 07/21/2017)